Lorvotuzumab Mertansine
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Lorvotuzumab Mertansine, covering 2018-08-28 to 2019-08-29. Get the full timeline:
Most recent: Clinical Trial Update: Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma [Phase 2]